Overview
Legal name
PLATINA BIOMED LTD
Region
South East England
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Platina Biomed Ltd
Platina Biomed Limited A NANOIMAGING COMPANY
Platina Biomed Ltd is a UK company with status active founded in 2017 based in South East England.
CRN
10774762
Founded
2017
Age
8
Corporate ownership
Updated 06 Jun 2026 16:52
Platina Biomed Ltd
No active corporate controller recorded.
Company events
Reference milestones and recent Companies House filing stream events.
5 events
05 Nov
2024
Gazette Dissolved Voluntary
GazetteGAZ2(A) | Transaction MzQ0MTMyOTQyNGFkaXF6a2N4 | Paper/PDF filed
Published 01 Nov 2024 01:34
20 Aug
2024
Gazette Notice Voluntary
GazetteGAZ1(A) | Transaction MzQzMTg0MDc0MmFkaXF6a2N4 | Paper/PDF filed
Published 16 Aug 2024 12:27
12 Aug
2024
Dissolution Application Strike Off Company
DissolutionDS01 | Transaction MzQzMTc4OTA1MWFkaXF6a2N4
Published 12 Aug 2024 11:39
10 Aug
2024
Accounts With Accounts Type Micro Entity
Accounts Awaiting analysisAA | Transaction MzQzMTc4OTAyNmFkaXF6a2N4
Published 10 Aug 2024 19:00
17 May
2017
Incorporated
InceptionCompany registered at Companies House
Public funding
2 awards
First funded
2018
Funded years
2018, 2020
Age at first award
0 years
Projects
2020
Study
Lead participant
Patient Safe Tumour Imaging Contrast Agents
1 Jan 2020 to 30 Sep 2021
Awarded
£238,491
Total cost £340,702
According to the NHS, 43 million imaging procedures were performed in 2018 in the UK. Out of all imaging procedures, 12.8 million (approx. 30%) procedures were reperformed using an additional imaging technique (modality) due to the lack of imaging contrast resolution. This lead to patient treatment delays, operational inefficiencies and economic consequen...
2018
Feasibility Studies
Lead participant
Application of Clinical Biomarkers for the Development of Multimodal Imaging Agents
1 Apr 2018 to 31 Mar 2019
Awarded
£68,195
Total cost £97,422
"Incorrect assignment of cancer stage in advanced-cancer-patients is responsible for the incorrect choice of first-line cancer therapy leading to increased-mortality(1.5-2x) and lowered-survival (less than 12 months) in as-many-as 25% of all patients diagnosed with cancer in the UK. Contrast-enhanced MR and CT imaging are the most common imaging modalitie...
Product types
Feasibility Studies
Study